Emerging Data on ACS Management From ACC

Slides:

Advertisements

Similar presentations

? What more will it take to turn the tide of treatment for angina patients from a PCI-first to an optimal medical therapy– first approach? 1.

Advertisements

Antiplatelet Therapy Use after Discharge among Acute Myocardial Infarction Patients with In-hospital Bleeding Tracy Y. Wang, MD, MHS, Lan Xiao, PhD, Karen.

수요저널 우종신. ACC/AHA Guideline Focused Update 2011 Class I 1. After PCI, use of aspirin should be continued indefinitely. (Level of Evidence.

Learning Objectives. Learning Objectives Variable Response to Clopidogrel.

PCSK9 Inhibitors Post-CVOTs

Preventing Thrombotic Complications in ACS: State of the Art

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons From Clinical Trials.

Know Your ABCs: Antiplatelet Therapy, Benefits/Bleeding, and Cardiac Surgery State of the Art: The Role of Antiplatelet Therapy in the Cardiac Surgical.

A Paradigm Shift in PAH.

Hyperkalemia in the Hospital: Collaboration to Improve Transitions of Care.

Achieving Long-Term Protection Post-MI

When Is Adding Aspirin to NOACs Worth the Risk?

Applying New Data in Practice:

At The Cutting Edge of Developments in the Management of Hyperkalemia

PAD Patients vs Post-ACS Patients:

Glenn N. Levine et al. JACC 2016;68:

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.

Medication Nonadherence in Gout

Advances in Dyslipidemia: What Have We Learned From ACC 2017

Antiplatelet Therapy Post-ACS: Bridging the CAD Continuum

What Has Been Tried and What Is True?

Tailoring Antiplatelet Therapy in PCI

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

Antiplatelet Therapy and Secondary Prevention

An Update on PCSK9 Inhibitors

New Pathways in Lipid Care

NOACS: Emerging data in ACS/IHD

Efficacy and Safety of Edoxaban in Patients With AF and HF

PCSK9 Inhibitors and Cardiovascular Outcomes

Comparison of US and European Guidelines Oral Antiplatelet Therapy in Primary PCI/STEMI.

Advancing Acute Coronary Syndrome Assessment:

A Better Solution For Cancer Patients With VTE?

PCSK9 Inhibitors – A Leap in the Evolution of Dyslipidemia Management?

Improving Appropriate Access to PCSK9 Inhibitors

Figure 2 Ischaemic and bleeding outcomes in the major clinical trials

Using Heart Rate as a Biomarker in Clinical Practice.

Multidisciplinary Management of Hyperkalemia:

Anticoagulation and Thrombosis Management

Overview. Complex Cases in PCI: Tailoring Antiplatelet Therapy to Improve Outcomes.

Aspirin and Cardioprevention in 2018

Clinicians' Corner in Dyslipidemia

Antiplatelet Therapy Use after Discharge among Acute Myocardial Infarction Patients with In-hospital Bleeding Tracy Y. Wang, MD, MHS, Lan Xiao, PhD, Karen.

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

Duration of Dual Antiplatelet Therapy

EXPLORE Trial design: Patients with STEMI treated with primary PCI and with evidence of noninfarct artery chronic total occlusion (CTO) were randomized.

Trials and Tribulations in VTE: How Do Real-World Data Fit In?

T2DM, CV Risk, and SGLT2 Inhibition in the Spotlight

Addressing Access to PCSK9 Inhibitors: Tips and Tools for Practicing Clinicians.

LDL Cholesterol.

How to Optimize Cholesterol Management in High-Risk CV Patients

Elevated Admission Plasma Glucose Following ACS

Tackling CV Risk in Type 2 Diabetes -- Gaps Between Guidelines and Clinical Practice?

Improving Adherence to Antiplatelet Therapy After an ACS Event

DECLARE-TIMI 58.

Assessing the Burden of Hyperkalemia

Antiplatelet Therapy Post-ACS: Bridging the CAD Continuum

An Update on PCSK9 Inhibitors

Assessing the Burden of Hyperkalemia

Championing Evidence-Based Care in Patients With Acute Low Back Pain

Introduction. Welcome to this program, titled De-Escalating Therapy in Epilepsy: A Return to Monotherapy.

ESC Guideline on the Management of STEMI Recommendation for DAPT

Figure 3. Trials and possible strategies for un-guided and guided DAPT de-escalation. The figure shows studies and strategies on DAPT de-escalation approaches.

Expert Perspectives.

PCSK9 Inhibitors and Real-World Evidence

Shared-Decision Making in Dyslipidemia

The Power of As-Treated Analyses

Antithrombotic Therapy in AF Patients Undergoing PCI

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Presentation transcript:

Emerging Data on ACS Management From ACC

Assessing the Impact of Medication Affordability on Prescribing Patterns and Patient Adherence

Background

Hypotheses

ARTEMIS: Study Design

ARTEMIS: Clinicians Are Sensitive to Patient Costs

ARTEMIS Non-Persistence of P2Y12 Inhibitor

ARTEMIS MACE and As-Treated Analysis

Conclusions/Clinical Pearls

Exploring the Safety of P2Y12 Inhibitors in STEMI Patients Receiving Fibrinolytic Therapy

TREAT Study Fills PLATO Study Gap

TREAT Trial: Design and Methods

TREAT Trial: Results

TREAT Study: Principal Findings (30 Days)

Conclusions/Clinical Pearls

The Correlation Between Prescription Supply and Medication Adherence After Acute Myocardial Infarction

30- vs 90-Day Prescription Supply Study: Background and Methods

30- vs 90-Day Prescription Supply Study: Results

30- vs 90-Day Prescription Supply Study: Results (Baseline Characteristics)

30- vs 90-Day Prescription Supply Study Results (Adherence and Product Changes)

Study Limitations

Conclusions/Clinical Pearls

The Clinical Implications of De-Escalating Antiplatelet Therapy

DAPT Guideline Recommendations

The Concept of De-Escalation

Prevalence and Timing of De-Escalation Therapy in Patients With ACS

Clinical Outcomes Associated With De-Escalation Therapy

SWAP-4 Study Design

SWAP-4 Study: Results and Conclusions

Conclusions/Clinical Pearls

Abbreviations

Abbreviations (cont)